Abcellera Biologics Inc (ABCL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abcellera Biologics Inc (ABCL) has a cash flow conversion efficiency ratio of -0.036x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.52 Million) by net assets ($938.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Abcellera Biologics Inc balance sheet independence to measure how much of total assets are equity-financed.
Abcellera Biologics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Abcellera Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Abcellera Biologics Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Abcellera Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abcellera Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KSB Ltd
NSE:KSB
|
0.019x |
|
Welspun Living Limited
NSE:WELSPUNLIV
|
N/A |
|
Zhejiang CONBA Pharmaceutical Co Ltd
SHG:600572
|
0.018x |
|
Globant SA
NYSE:GLOB
|
0.041x |
|
China Oilfield Services Limited
F:CO9
|
0.026x |
|
Allied Gold Corporation
NYSE:AAUC
|
0.432x |
|
Wafer Works
TWO:6182
|
0.005x |
|
Dicker Data Ltd
AU:DDR
|
0.188x |
Annual Cash Flow Conversion Efficiency for Abcellera Biologics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Abcellera Biologics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Abcellera Biologics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $966.90 Million | $-131.29 Million | -0.136x | -32.10% |
| 2024-12-31 | $1.06 Billion | $-108.56 Million | -0.103x | -169.95% |
| 2023-12-31 | $1.15 Billion | $-43.88 Million | -0.038x | -116.93% |
| 2022-12-31 | $1.23 Billion | $277.36 Million | 0.225x | -5.68% |
| 2021-12-31 | $1.03 Billion | $244.58 Million | 0.238x | +772.78% |
| 2020-12-31 | $830.51 Million | $22.69 Million | 0.027x | -89.60% |
| 2019-12-31 | $10.25 Million | $2.69 Million | 0.263x | -14.43% |
| 2018-12-31 | $11.61 Million | $3.56 Million | 0.307x | -- |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more